RxDoctor Payments Data

Marc Crisenbery, NP

Nurse Practitioner · Toledo, OHNPI 1881618841

Payments from drug & device makers

$2,207in general payments, 2019–2025

Across 33 payments — averaging $66.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • C. R. Bard, Inc. & Subsidiaries$184
  • Convatec Inc.$103
  • Astellas Pharma US Inc$85
  • Rochester Medical Corporation$58
  • 180 Medical, Inc.$45
  • plus $106 from 5 others

What the payments were for

  • Travel & lodging$1,22656%
  • Food & beverage$89641%
  • Education$854%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.12$1,625
C. R. Bard, Inc. & Subsidiaries7$184
Convatec Inc.4$103
Astellas Pharma US Inc1$85
Rochester Medical Corporation2$58
180 Medical, Inc.2$45
Angiodynamics, Inc.1$25
Boston Scientific1$23
Procept Biorobotics Corporation1$21
Vertex1$20
Johnson & Johnson1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,207 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$38,683
Medicare patients
288
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron67$43,783
Cinacalcet Hcl16$10,865
Mycophenolic AcidMycophenolate Sodium24$8,498
Tacrolimus39$4,456
Tamsulosin Hcl267$4,080
Oxybutynin Chloride ErOxybutynin Chloride66$1,943
Solifenacin Succinate18$1,390
Testosterone16$1,070
Prednisone130$917
Finasteride90$852
Carvedilol53$555
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$500
Famotidine45$488
Potassium Chloride20$457
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$85$43,78367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →